AbCellera Biologics (ABCL) to Release Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect AbCellera Biologics to post earnings of ($0.16) per share for the quarter. Individual interested in participating in the company’s conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCL) last announced its earnings results on Tuesday, February 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 12.36% and a negative net margin of 384.99%. The company had revenue of $9.18 million for the quarter, compared to the consensus estimate of $9.58 million. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Stock Up 2.1 %

NASDAQ:ABCL opened at $3.84 on Tuesday. The company’s 50 day moving average is $4.53 and its 200-day moving average is $4.80. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -7.38 and a beta of 0.36. AbCellera Biologics has a 12 month low of $3.62 and a 12 month high of $8.05.

Analyst Ratings Changes

ABCL has been the topic of several research analyst reports. Benchmark upgraded shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Thursday, February 22nd. Stifel Nicolaus lowered their price target on AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 21st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, AbCellera Biologics has an average rating of “Buy” and an average target price of $15.86.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.